Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 481–490 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 481
- Medicine slug
- doxycycline
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 234
- Source count
- 8
- Agreement rate
- 0.875
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a18d4c7-9484-4d3e-b61b-e81fe63fefec (opens source in a new tab)
Doxycycline label
Version not recorded · Effective date not recorded
tion of doxycycline hyclate delayed-release tablets, 200 mg to adult volunteers, average peak plasma doxycycline concentration (C max ) was 4.6 mcg/mL and 6.3 mcg/mL, respectively with median t max of 3 hours; the corresponding mean plasma concentration values 24 hours after single and multiple doses were 1.5 mcg/mL and 2.3 mcg/mL, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5ee43b2-d6ca-4819-a3d7-07f8421015d7 (opens source in a new tab)
Doxycycline label
Version not recorded · Effective date not recorded
tion of doxycycline hyclate delayed-release tablets, 200 mg to adult volunteers, average peak plasma doxycycline concentration (C max ) was 4.6 mcg/mL and 6.3 mcg/mL, respectively with median t max of 3 hours; the corresponding mean plasma concentration values 24 hours after single and multiple doses were 1.5 mcg/mL and 2.3 mcg/mL, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd2ab9b8-9619-4199-8a5d-83377b3274d1 (opens source in a new tab)
Doxycycline label
Version not recorded · Effective date not recorded
tion of doxycycline hyclate delayed-release tablets, 200 mg to adult volunteers, average peak plasma doxycycline concentration (C max ) was 4.6 mcg/mL and 6.3 mcg/mL, respectively with median t max of 3 hours; the corresponding mean plasma concentration values 24 hours after single and multiple doses were 1.5 mcg/mL and 2.3 mcg/mL, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ae4ca12-be39-46b9-bc4c-f8356776c175 (opens source in a new tab)
Doxycycline label
Version not recorded · Effective date not recorded
tion of doxycycline hyclate delayed-release tablets, 200 mg to adult volunteers, average peak plasma doxycycline concentration (C max ) was 4.6 mcg/mL and 6.3 mcg/mL, respectively with median t max of 3 hours; the corresponding mean plasma concentration values 24 hours after single and multiple doses were 1.5 mcg/mL and 2.3 mcg/mL, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2b08332-3256-4658-965a-ede3d973a388 (opens source in a new tab)
Doxycycline label
Version not recorded · Effective date not recorded
tion of doxycycline hyclate delayed-release tablets, 200 mg to adult volunteers, average peak plasma doxycycline concentration (C max ) was 4.6 mcg/mL and 6.3 mcg/mL, respectively with median t max of 3 hours; the corresponding mean plasma concentration values 24 hours after single and multiple doses were 1.5 mcg/mL and 2.3 mcg/mL, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44ac5de1-c0c6-4d58-9a49-b2dae60ea921 (opens source in a new tab)
Doxycycline label
Version not recorded · Effective date not recorded
tion of doxycycline hyclate delayed-release tablets, 200 mg to adult volunteers, average peak plasma doxycycline concentration (C max ) was 4.6 mcg/mL and 6.3 mcg/mL, respectively with median t max of 3 hours; the corresponding mean plasma concentration values 24 hours after single and multiple doses were 1.5 mcg/mL and 2.3 mcg/mL, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4fa26176-a730-48ed-9659-e2f64212f418 (opens source in a new tab)
Doxycycline label
Version not recorded · Effective date not recorded
Following single and multiple-dose administration of doxycycline hyclate delayed-release tablets, 200 mg to adult volunteers, average peak plasma doxycycline concentration (C max ) was 4.6 mcg/mL and 6.3 mcg/mL, respectively with median t max of 3 hours; the corresponding mean plasma concentration values 24 hours after single and multiple doses were 1.5 mcg/mL and 2.3 mcg/mL, respectively.
2.8 hours
- Numeric value
- 2.8
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9277bb8-982d-444d-9325-35d5c53a2d35 (opens source in a new tab)
Doxycycline label
Version not recorded · Effective date not recorded
The Tmax was 2.8 hours.
Projected row 482
- Medicine slug
- dronabinol
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
4 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44205ae6-b86a-485c-baf6-233a2c878640 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Published data showed an increase in the elimination half-life of pentobarbital by 4 hours when concomitantly dosed with dronabinol [see Warnings and Precautions (5.1) ] . 12.5 Pharmacogenomics Published data indicate a 2- to 3-fold higher dronabinol exposure in individuals carrying genetic variants associated with diminished CYP2C9 function.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:628f9609-6583-49be-be77-b64cfbc46fd7 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Published data showed an increase in the elimination half-life of pentobarbital by 4 hours when concomitantly dosed with dronabinol [see Warnings and Precautions (5.1)] . 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dronabinol is an orally active cannabinoid which has complex effects on the CNS, including central sympathomimetic activity.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cdcb4f5-5af9-4ff7-b535-2a5cf4c6da89 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Published data showed an increase in the elimination half-life of pentobarbital by 4 hours when concomitantly dosed with dronabinol [see Warnings and Precautions ( 5.1 )] . 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dronabinol is an orally active cannabinoid that has complex effects on the CNS, including central sympathomimetic activity.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adb1801c-0fb5-4e16-b969-1db91230e0b9 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Published data showed an increase in the elimination half-life of pentobarbital by 4 hours when concomitantly dosed with dronabinol [see Warnings and Precautions ( 5.1 )]. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dronabinol is an orally active cannabinoid which has complex effects on the CNS, including central sympathomimetic activity.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd8c5d57-0173-4f62-8ff0-d8147986a976 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Published data showed an increase in the elimination half-life of pentobarbital by 4 hours when concomitantly dosed with dronabinol [see Warnings and Precautions ( 5.1 )]. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dronabinol is an orally active cannabinoid which has complex effects on the CNS, including central sympathomimetic activity.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7801c70-995d-46a2-91ee-141ef427c6b5 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Published data showed an increase in the elimination half-life of pentobarbital by 4 hours when concomitantly dosed with dronabinol [see Warnings and Precautions ( 5.1 )] . 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dronabinol is an orally active cannabinoid that has complex effects on the CNS, including central sympathomimetic activity.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0efeeec-640d-43c3-8f0a-d31324a11c68 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Published data showed an increase in the elimination half-life of pentobarbital by 4 hours when concomitantly dosed with dronabinol [see Warnings and Precautions ( 5.1 )]. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dronabinol is an orally active cannabinoid which has complex effects on the CNS, including central sympathomimetic activity.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:495aabae-3597-49dc-a5af-e328bcd937b7 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Published data showed an increase in the elimination half-life of pentobarbital by 4 hours when concomitantly dosed with dronabinol [see Warnings and Precautions ( 5.1 )] . 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dronabinol is an orally active cannabinoid that has complex effects on the CNS, including central sympathomimetic activity.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:66f36fe0-9808-4b73-a99a-794d86ff0c1c (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Published data showed an increase in the elimination half-life of pentobarbital by 4 hours when concomitantly dosed with dronabinol [see Warnings and Precautions (5.1)] . abs 12.5 Pharmacogenomics Published data indicate a potentially 2-to 3-fold higher dronabinol exposure in individuals carrying genetic variants associated with diminished CYP2C9 function.
Projected row 483
- Medicine slug
- dronabinol
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
97%
- Numeric value
- 97
- Unit
- %
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44205ae6-b86a-485c-baf6-233a2c878640 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
The plasma protein binding of dronabinol and its metabolites is approximately 97% [see Drug Interactions (7.3) ] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:628f9609-6583-49be-be77-b64cfbc46fd7 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
The plasma protein binding of dronabinol and its metabolites is approximately 97% [see Drug Interactions (7.4)] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cdcb4f5-5af9-4ff7-b535-2a5cf4c6da89 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
The plasma protein binding of dronabinol and its metabolites is approximately 97% [see Drug Interactions ( 7.3 )] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adb1801c-0fb5-4e16-b969-1db91230e0b9 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
The plasma protein binding of dronabinol and its metabolites is approximately 97% [see Drug Interactions ( 7.4 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd8c5d57-0173-4f62-8ff0-d8147986a976 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
The plasma protein binding of dronabinol and its metabolites is approximately 97% [see Drug Interactions ( 7.4 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7801c70-995d-46a2-91ee-141ef427c6b5 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
The plasma protein binding of dronabinol and its metabolites is approximately 97% [see Drug Interactions ( 7.3 )] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0efeeec-640d-43c3-8f0a-d31324a11c68 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
The plasma protein binding of dronabinol and its metabolites is approximately 97% [see Drug Interactions ( 7.4) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:495aabae-3597-49dc-a5af-e328bcd937b7 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
The plasma protein binding of dronabinol and its metabolites is approximately 97% [see Drug Interactions ( 7.3 )] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:66f36fe0-9808-4b73-a99a-794d86ff0c1c (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
The plasma protein binding of dronabinol and its metabolites is approximately 97% [see Drug Interactions (7.4)] .
Projected row 484
- Medicine slug
- dronabinol
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
10 L/kg
- Numeric value
- 10
- Unit
- L/kg
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44205ae6-b86a-485c-baf6-233a2c878640 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Distribution Dronabinol has an apparent volume of distribution of approximately 10 L/kg, because of its lipid solubility.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:628f9609-6583-49be-be77-b64cfbc46fd7 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Distribution Dronabinol has an apparent volume of distribution of approximately 10 L/kg, because of its lipid solubility.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cdcb4f5-5af9-4ff7-b535-2a5cf4c6da89 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Distribution Dronabinol has an apparent volume of distribution of approximately 10 L/kg, because of its lipid solubility.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adb1801c-0fb5-4e16-b969-1db91230e0b9 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Distribution Dronabinol has an apparent volume of distribution of approximately 10 L/kg, because of its lipid solubility.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd8c5d57-0173-4f62-8ff0-d8147986a976 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Distribution Dronabinol has an apparent volume of distribution of approximately 10 L/kg, because of its lipid solubility.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7801c70-995d-46a2-91ee-141ef427c6b5 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Distribution Dronabinol has an apparent volume of distribution of approximately 10 L/kg, because of its lipid solubility.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0efeeec-640d-43c3-8f0a-d31324a11c68 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Distribution Dronabinol has an apparent volume of distribution of approximately 10 L/kg, because of its lipid solubility.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:495aabae-3597-49dc-a5af-e328bcd937b7 (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Distribution Dronabinol has an apparent volume of distribution of approximately 10 L/kg, because of its lipid solubility.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:66f36fe0-9808-4b73-a99a-794d86ff0c1c (opens source in a new tab)
Dronabinol label
Version not recorded · Effective date not recorded
Distribution Dronabinol has an apparent volume of distribution of approximately 10 L/kg, because of its lipid solubility.
Projected row 485
- Medicine slug
- dronedarone
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
4%
- Numeric value
- 4
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (opens source in a new tab)
Dronedarone label
Version not recorded · Effective date not recorded
Absorption Because of presystemic first pass metabolism the absolute bioavailability of dronedarone without food is low, about 4%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bd4006a-8bad-4909-ac6d-b6d84390155c (opens source in a new tab)
Dronedarone label
Version not recorded · Effective date not recorded
Absorption Because of presystemic first pass metabolism the absolute bioavailability of dronedarone without food is low, about 4%.
Projected row 486
- Medicine slug
- dronedarone
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
13 to 19 hours
- Numeric value
- 13
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (opens source in a new tab)
Dronedarone label
Version not recorded · Effective date not recorded
Its elimination half-life is 13 to 19 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bd4006a-8bad-4909-ac6d-b6d84390155c (opens source in a new tab)
Dronedarone label
Version not recorded · Effective date not recorded
Its elimination half-life is 13 to 19 hours.
Projected row 487
- Medicine slug
- dronedarone
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
>98%
- Numeric value
- 98
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (opens source in a new tab)
Dronedarone label
Version not recorded · Effective date not recorded
Distribution The in vitro plasma protein binding of dronedarone and its N-debutyl metabolite is >98% and not saturable.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bd4006a-8bad-4909-ac6d-b6d84390155c (opens source in a new tab)
Dronedarone label
Version not recorded · Effective date not recorded
Distribution The in vitro plasma protein binding of dronedarone and its N-debutyl metabolite is >98% and not saturable.
Projected row 488
- Medicine slug
- dronedarone
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
1400 L
- Numeric value
- 1,400
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (opens source in a new tab)
Dronedarone label
Version not recorded · Effective date not recorded
After intravenous (IV) administration the volume of distribution at steady state is about 1400 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bd4006a-8bad-4909-ac6d-b6d84390155c (opens source in a new tab)
Dronedarone label
Version not recorded · Effective date not recorded
After intravenous (IV) administration the volume of distribution at steady state is about 1400 L.
Projected row 489
- Medicine slug
- droxidopa
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
2.5 hours
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6dce609-c7d7-48a3-83bb-32ecf00f973f (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Excretion The mean elimination half-life of droxidopa is approximately 2.5 hours in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff263c9a-3db2-45ac-9ba6-8fca47199604 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Excretion The mean elimination half-life of droxidopa is approximately 2.5 hours in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:381ffe44-d5d8-4380-a3cd-6d6a5e9ef55d (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Excretion The mean elimination half-life of droxidopa is approximately 2.5 hours in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10b02d98-ebb8-4152-bd56-3402417fbf79 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Excretion The mean elimination half-life of droxidopa is approximately 2.5 hours in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6091958e-f04e-47c0-9eef-9c204df4edd9 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Excretion The mean elimination half-life of droxidopa is approximately 2.5 hours in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51ef3096-4622-4f45-a180-ab0dc6d46df9 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Excretion The mean elimination half-life of droxidopa is approximately 2.5 hours in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:049f997b-1649-467e-bbb9-bdb991b0bc6e (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Excretion The mean elimination half-life of droxidopa is approximately 2.5 hours in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c21ea27c-6e3b-4296-a118-c0b878cdf8f8 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Excretion The mean elimination half-life of droxidopa is approximately 2.5 hours in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04b1f69d-ebba-43b9-8ecd-4f6be7c8a0a0 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Excretion The mean elimination half-life of droxidopa is approximately 2.5 hours in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3cfd280-3548-b590-e053-2a95a90a5eb3 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Excretion The mean elimination half-life of droxidopa is approximately 2.5 hours in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa3ce55a-1ea9-4b50-b682-6f25398bcc29 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Excretion The mean elimination half-life of droxidopa is approximately 2.5 hours in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe08aebb-b390-d176-e053-6394a90a6be7 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Excretion The mean elimination half-life of droxidopa is approximately 2.5 hours in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81b798dc-b8dc-48a5-af46-82bb55f789a8 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Excretion The mean elimination half-life of droxidopa is approximately 2.5 hours in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2179f02c-48d7-48eb-8007-5ae43d8d16bc (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Excretion The mean elimination half-life of droxidopa is approximately 2.5 hours in humans.
Projected row 490
- Medicine slug
- droxidopa
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
75%
- Numeric value
- 75
- Unit
- %
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6dce609-c7d7-48a3-83bb-32ecf00f973f (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff263c9a-3db2-45ac-9ba6-8fca47199604 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:381ffe44-d5d8-4380-a3cd-6d6a5e9ef55d (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10b02d98-ebb8-4152-bd56-3402417fbf79 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6091958e-f04e-47c0-9eef-9c204df4edd9 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51ef3096-4622-4f45-a180-ab0dc6d46df9 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:049f997b-1649-467e-bbb9-bdb991b0bc6e (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c21ea27c-6e3b-4296-a118-c0b878cdf8f8 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04b1f69d-ebba-43b9-8ecd-4f6be7c8a0a0 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3cfd280-3548-b590-e053-2a95a90a5eb3 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa3ce55a-1ea9-4b50-b682-6f25398bcc29 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe08aebb-b390-d176-e053-6394a90a6be7 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81b798dc-b8dc-48a5-af46-82bb55f789a8 (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2179f02c-48d7-48eb-8007-5ae43d8d16bc (opens source in a new tab)
Droxidopa label
Version not recorded · Effective date not recorded
Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=480Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.